Vermillion Inc (NASDAQ:VRML):
Vermillion Announces Publication of Foundational Health Economics Study.
In the market the company is trading up by 1.36% since yesterday’s close of 1.47.
Vermillion, Inc., launched on May 23, 2000, is a diagnostic service and bio-analytic solutions provider. The Company is involved in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). The Business’s OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. The Company developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated..
Vermillion Inc currently has a P/E ratio of N/A and the market cap is 89.40M. In the latest earnings report the EPS was $-0.21 with 60.00M shares now outstanding.
Investors are feeling more bullish on the company lately as indicated by the downtick in short interest. The company experienced a fall in short interest of -9.21% as of the latest report on October 13, 2017. Short interest fell 73,481 over that period. The days to cover increased to 17.0 and the short interest percentage is 0.01% as of October 13.
A few brokerage analysts have released opinions on VRML of late. Canaccord Genuity raised the price target of the stock on November 2 changing the price objective from $1.75 to $2.25 with a rating of “Buy”. On August 30 Canaccord Genuity left the stock rating at “Buy” targeting a price of $1.75.